ARTICLE | Finance
Public Equity Report: Artiva’s debut comes amid underwhelming IPO season
$167M raise by NK cell therapy company highlight of slow week for public equity
July 20, 2024 1:41 AM UTC
The second time at an IPO was the charm for NK cell therapy company Artiva, which raised $167 million on Thursday in an upsized offering during a week in which venture financings overshadowed those by public companies.
The deal by Artiva Biotherapeutics Inc. (NASDAQ:ARTV) is largely good news for an IPO market that has underwhelmed this year. According to BioCentury’s 3Q24 Public Markets Preview, bankers expect the biggest names to look to go public toward the start of 2025, when investor risk appetites might be more amenable to new listings...